CNS Pharmaceuticals gets final Nasdaq extension to Aug 12 for equity compliance

CNS Pharmaceuticals, Inc.

Nasdaq Panel granted extension until August 12, 2024 to meet $2.5M stockholders' equity requirement.
Company previously failed to comply with Listing Rule 5550(b) and requested hearing.
This is the full extent of the Panel's discretion; failure to comply may lead to delisting.

item 3.01

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-005023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.